REFERENCES
- Coombes R C, Hall E, Gibson L J, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 1081–1092, [PUBMED], [INFOTRIEVE], [CSA]
- Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr. 2001; 56–61, [CSA]
- Shapiro C L, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001; 344: 1997–2008, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hoda D, Perez D G, Loprinzi C L. Hot flashes in breast cancer survivors. Breast J. 2003; 9: 431–438, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60–62, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Deitcher S R, Gomes M P. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: A systematic review. Cancer 2004; 101: 439–449, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mourits M J, De Vries E G, Willemse P H, et al. Tamoxifen treatment and gynecologic side effects: A review. Obstet Gynecol. 2001; 97: 855–866, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gorin M B, Day R, Costantino J P, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998; 125: 493–501, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Noureddin B N, Seoud M, Bashshur Z, et al. Ocular toxicity in low-dose tamoxifen: A prospective study. Eye 1999; 13(Pt 6)729–733, [PUBMED], [INFOTRIEVE], [CSA]
- Pavlidis N A, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992; 69: 2961–2964, [PUBMED], [INFOTRIEVE], [CSA]
- Fraunfelder F T, Fraunfelder F W. Drug-Induced Ocular Side Effects5th ed. Butterworth-Heinemann, Boston 2001; 471–474
- Nayfield S G, Gorin M B. Tamoxifen-associated eye disease. A review. J Clin Oncol. 1996; 14: 1018–1026, [PUBMED], [INFOTRIEVE], [CSA]
- Therssen R, Jansen E, Leys A, Rutten J, Meyskens J. Screening for tamoxifen ocular toxicity: A prospective study. Eur J Ophthalmol. 1995; 5: 230–234, [PUBMED], [INFOTRIEVE], [CSA]
- Colley S M, Elston J S. Tamoxifen optic neuropathy. Clin Exp. Ophthalmol. 2004; 32: 105–106, [CROSSREF], [CSA]
- Ashford A R, Donev I, Tiwari R P, Garrett T J. Reversible ocular toxicity related to tamoxifen therapy. Cancer 1988; 61: 33–35, [PUBMED], [INFOTRIEVE], [CSA]
- Pugesgaard T, Von Eyben F E. Bilateral optic neuritis evolved during tamoxifen treatment. Cancer 1986; 58: 383–386, [PUBMED], [INFOTRIEVE], [CSA]
- Eisner A, Austin D F, Samples J R. Short wavelength automated perimetry and tamoxifen use. Br J Ophthalmol. 2004; 88: 125–130, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Eisner A, Incognito L J. The color appearance of stimuli detected via short-wavelength-sensitive cones for breast cancer survivors using tamoxifen. Vision Res. 2006; 46: 1816–1822, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye 1997; 11(Pt 3)295–297, [PUBMED], [INFOTRIEVE], [CSA]
- Heier J S, Dragoo R A, Enzenauer R W, Waterhouse W J. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol. 1994; 117: 772–775, [PUBMED], [INFOTRIEVE], [CSA]
- Greenfield D S. Optic nerve and retinal nerve fiber layer analyzers in glaucoma. Curr Opin Ophthalmol. 2002; 13: 68–76, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Airaksinen P J, Tuulonen A, Werner E B. Clincial evaluation of the optic disc and retinal nerve fiber layer. The Glaucomas: Basic Sciences2nd ed., R Ritch, M B Shields, T Krupin. Mosby, St. Louis 1996; vol 1: 617–657
- Bowd C, Zangwill L M, Blumenthal E Z, et al. Imaging of the optic disc and retinal nerve fiber layer: The effects of age, optic disc area, refractive error, and gender. J Opt Soc Am A Opt Image Sci Vis. 2002; 19: 197–207, [PUBMED], [INFOTRIEVE], [CSA]
- Jentsch T J, Stein V, Weinreich F, Zdebik A A. Molecular structure and physiological function of chloride channels. Physiol Rev. 2002; 82: 503–568, [PUBMED], [INFOTRIEVE], [CSA]
- Sardini A, Amey J S, Weylandt K H, et al. Cell volume regulation and swelling-activated chloride channels. Biochim Biophys Acta. 2003; 1618: 153–162, [PUBMED], [INFOTRIEVE], [CSA]
- Minckler D S, McLean I W, Tso M O. Distribution of axonal and glial elements in the rhesus optic nerve head studied by electron microscopy. Am J Ophthalmol. 1976; 82: 179–187, [PUBMED], [INFOTRIEVE], [CSA]
- Hernandez M R. The optic nerve head in glaucoma: Role of astrocytes in tissue remodeling. Prog Retin Eye Res. 2000; 19: 297–321, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kimelberg H K. Increased release of excitatory amino acids by the actions of ATP and peroxynitrite on volume-regulated anion channels (VRACs) in astrocytes. Neurochem Int. 2004; 45: 511–519, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kimelberg H K. Astrocytic swelling in cerebral ischemia as a possible cause of injury and target for therapy. Glia. 2005; 50: 389–397, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Adams A J, Rodic R, Husted R, Stamper R. Spectral sensitivity and color discrimination changes in glaucoma and glaucoma-suspect patients. Invest Ophthalmol Vis Sci. 1982; 23: 516–524, [PUBMED], [INFOTRIEVE], [CSA]
- Loprinzi C L, Zahasky K M, Sloan J A, et al. Tamoxifen-induced hot flashes. Clin Breast Cancer 2000; 1: 52–56, [PUBMED], [INFOTRIEVE], [CSA]
- Clemons M, Danson S, Howell A. Tamoxifen (“Nolvadex”): A review. Cancer Treat Rev. 2002; 28: 165–180, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- HRTII Heidelberg Engineering product brochure “How to read the printout.” Available at http://www.heidelbergengineering.com/
- Zangwill L M, Weinreb R N, Berry C C, et al. The confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study: Study design and baseline factors. Am J Ophthalmol. 2004; 137: 219–227, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hermann M M, Theofylaktopoulos I, Bangard N, et al. Optic nerve head morphometry in healthy adults using confocal laser scanning tomography. Br J Ophthalmol. 2004; 88: 761–765, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Durukan A H, Yucel I, Akar Y, Bayraktar M Z. Assessment of optic nerve head topographic parameters with a confocal scanning laser ophthalmoscope. Clin Exp. Ophthalmol. 2004; 32: 259–264, [CROSSREF], [CSA]
- Gherghel D, Orgul S, Prunte C, et al. Interocular differences in optic disc topographic parameters in normal subjects. Curr Eye Res. 2000; 20: 276–282, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Saruhan A, Orgul S, Kocak I, et al. Descriptive information of topographic parameters computed at the optic nerve head with the Heidelberg retina tomograph. J Glaucoma. 1998; 7: 420–429, [PUBMED], [INFOTRIEVE], [CSA]
- Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol. 1998; 25: 1032–1037, [PUBMED], [INFOTRIEVE], [CSA]
- Zhang J J, Jacob T J. Volume regulation in the bovine lens and cataract. The involvement of chloride channels. J Clin Invest. 1996; 97: 971–978, [PUBMED], [INFOTRIEVE], [CSA]
- Soto D, Comes N, Ferrer E, et al. Modulation of aqueous humor outflow by ionic mechanisms involved in trabecular meshwork cell volume regulation. Invest Ophthalmol Vis Sci. 2004; 45: 3650–3661, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Srinivas S P, Guan Y, Bonanno J A. Swelling activated chloride channels in cultured bovine corneal endothelial cells. Exp Eye Res. 1999; 68: 165–177, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Burk R O, Vihanninjoki K, Bartke T, et al. Development of the standard reference plane for the Heidelberg retina tomograph. Graefes Arch Clin Exp Ophthalmol. 2000; 238: 375–384, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- MacVicar B A, Feighan D, Brown A, Ransom B. Intrinsic optical signals in the rat optic nerve: Role for K(+) uptake via NKCC1 and swelling of astrocytes. Glia. 2002; 37: 114–123, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Darby M, Kuzmiski J B, Panenka W, et al. ATP released from astrocytes during swelling activates chloride channels. J Neurophysiol. 2003; 89: 1870–1877, [PUBMED], [INFOTRIEVE], [CSA]
- Chamberlain M C, Kormanik P A. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol. 1999; 56: 703–708, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Batistatou A, Stefanou D, Goussia A, et al. Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J Cancer Res Clin Oncol. 2004; 130: 405–410, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Olsen M L, Schade S, Lyons S A, et al. Expression of voltage-gated chloride channels in human glioma cells. J Neurosci. 2003; 23: 5572–5582, [PUBMED], [INFOTRIEVE], [CSA]
- Morgan W H, Chauhan B C, Yu D Y, et al. Optic disc movement with variations in intraocular and cerebrospinal fluid pressure. Invest Ophthalmol Vis Sci. 2002; 43: 3236–3242, [PUBMED], [INFOTRIEVE], [CSA]
- Kaiser-Kupfer M I, Kupfer C, Rodrigues M M. Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology 1981; 88: 89–93, [PUBMED], [INFOTRIEVE], [CSA]
- Akar M E, Taskin O, Yucel I, Akar Y. The effect of the menstrual cycle on optic nerve head analysis in healthy women. Acta Ophthalmol Scand. 2004; 82: 741–745, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vernon S A, Hawker M J, Ainsworth G, et al. Laser scanning tomography of the optic nerve head in a normal elderly population: The Bridlington eye assessment project. Invest Ophthalmol Vis Sci. 2005; 46: 2823–2828, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nascimento D S, Reis C U, Goldenberg R C, et al. Estrogen modulates ClC-2 chloride channel gene expression in rat kidney. Pflugers Arch. 2003; 446: 593–599, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pawlak J, Karolczak M, Krust A, et al. Estrogen receptor-alpha is associated with the plasma membrane of astrocytes and coupled to the MAP/Src-kinase pathway. Glia. 2005; 50: 270–275, [PUBMED], [INFOTRIEVE], [CSA]
- Gallicchio L, Lord G, Tkaczuk K, et al. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res Treat. 2004; 85: 89–97, [PUBMED], [INFOTRIEVE], [CSA]
- Moorthy R S, Valluri S. Ocular toxicity associated with systemic drug therapy. Curr Opin Ophthalmol. 1999; 10: 438–446, [PUBMED], [INFOTRIEVE], [CSA]
- Baker V L, Jaffe R B. Clinical uses of antiestrogens. Obstet Gynecol Surv. 1996; 51: 45–59, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Purvin V A. Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol. 1995; 113: 482–484, [PUBMED], [INFOTRIEVE], [CSA]
- Fraunfelder F T, Fraunfelder F W. Drug-Induced Ocular Side Effects5th ed. Butterworth Heinemann, Boston 2001; 374–377
- Maertens C, Droogmans G, Chakraborty P, Nilius B. Inhibition of volume-regulated anion channels in cultured endothelial cells by the anti-oestrogens clomiphene and nafoxidine. Br J Pharmacol. 2001; 132: 135–142, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tobias J S. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: Implications for treatment and prevention. Ann Oncol. 2004; 15: 1738–1747, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ali S, Coombes R C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101–112, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11: 643–658, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005; 23: 5138–5147, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]